Research project CoVaLux

CoVaLux – COVID-19, vaccination & long-term health consequences of COVID-19 in Luxembourg

CoVaLux aims to address key unanswered questions related to COVID-19, specifically on vaccination and the longer-term health impact of COVID-19.

The project at a glance

  • Start date:
    01 Dec 2021
  • Duration in months:
    36
  • Funding:
    Ministry of Higher Education and Research / Ministry of Health
  • Principal Investigator(s):
    Paul Wilmes
    Guy Fagherazzi (external)

About

CoVaLux focuses on the symptomatology, prevalence, and socio-economic and environmental determinants of Long COVID, as well as on the short- to mid-term impacts of vaccination in relation to the evolution of immunity, breakthrough infections by different variants, and re-infections. CoVaLux also aims to decipher the role of co-infections in COVID-19 and the role of other pathogens during and after the disease.

The study relies on previous national studies (Predi-COVID and CON-VINCE), and complementary data retrieved from different sources.

CoVaLux represents a coordinated effort at the national level to answer important unsolved questions related to COVID-19 and its consequences, relying on an interdisciplinary approach at the crossroads of immunology, psychology, epidemiology, digital health, social science and public health.

Website
Research Project LCSB COVALUX

Organisation and Partners

  • Luxembourg Centre for Systems Biomedicine (LCSB)
  • Systems Ecology
  • Research Luxembourg
  • Luxembourg Institute of Health (LIH)
  • Integrated Biobank of Luxembourg (IBBL)
  • Laboratoire national de santé (LNS)
  • Luxembourg Institute of Socio-Economic Research (LISER)
  • Luxembourg Institute of Science and Technology (LIST)
  • Centre Hospitalier de Luxembourg (CHL)
  • Centre Hospitalier Neuro-Psychiatrique (CHNP)

Project team

Keywords

  • COVID-19
  • Long COVID
  • vaccination

Share this